The demonstration of type 2 somatostatin receptors (SSTRs) in small-cell lung cancer (SCLC) represents the rationale for the use of positron emission tomography/computed tomography (PET/CT) to determine SSTR expression, and select patients suitable for peptide radioreceptor radionuclide therapy (PRRT) in extensive-disease stage (ED) SCLC.
Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients / Sollini, Martina; Farioli, Daniela; Froio, Armando; Chella, Antonio; Asti, Mattia; Boni, Roberto; Grassi, Elisa; Roncali, Massimo; Versari, Annibale; Erba, Paola Anna. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-0864. - STAMPA. - 8:8(2013), pp. 1095-1101. [10.1097/JTO.0b013e318293f051]
Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients
FARIOLI, DANIELA;
2013
Abstract
The demonstration of type 2 somatostatin receptors (SSTRs) in small-cell lung cancer (SCLC) represents the rationale for the use of positron emission tomography/computed tomography (PET/CT) to determine SSTR expression, and select patients suitable for peptide radioreceptor radionuclide therapy (PRRT) in extensive-disease stage (ED) SCLC.
| File | Dimensione | Formato | |
|---|---|---|---|
|
JTO.0b013e318293f051.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
1.96 MB
Formato
Adobe PDF
|
1.96 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
